Vaccines

Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy

by Umm E. LailaUmm E. LailaWang AnWang AnZhi-Xiang Xu Zhi-Xiang Xu 24/11/2024 Frontiers

Cancer remains a significant global health challenge, with estimates projecting 34 million new cases by 2070 (1). Despite advancements in treatment, current therapies exhibit limitations, emphasizing the need for innovative solutions for cancer treatment. (2). The concept of mRNA cancer vaccines has emerged as a promising avenue for immunotherapy, following the success of mRNA technology in producing effective COVID-19 vaccines during the pandemic. (3–6). Immunotherapy, such as immune checkpoint inhibitors and CAR-T therapies, have revolutionized cancer treatment by harnessing the power of the immune system. (7). Recently, these approaches, combined with mRNA vaccines, offer a personalized and effective strategy against cancer, providing a more targeted approach

mRNA vaccines for HIV trigger strong immune response in people

by Smriti Mallapaty 1/8/25 nature

The trial is only the third to test mRNA vaccines against HIV. “These are the first studies, so they’re very, very important,” says infectious-disease physician Sharon Lewin, who heads the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia.

Addressing the Cold Reality of mRNA Vaccine Stability

by Daan J.A. Crommelin 3/21 ScienceDirect

As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain.

RNA vaccines articles from across Nature Portfolio

by nature portfolio

RNA vaccines are composed of the nucleic acid RNA, which encode antigen genes of an infectious agent. When administered to host cells, the RNA is translated into protein antigens that elicit protective immunity against the infectious agent.

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

by Brian J. Boyarsky JAMA

In contrast to immunocompetent participants in vaccine trials,1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody response to the first dose of SARS-CoV-2 messenger RNA (mRNA) vaccines, with those receiving anti–metabolite maintenance immunosuppression less likely to respond.3 In this study, we assessed antibody response after the second dose.